BMJ Sexual & Reproductive Health,
Journal Year:
2024,
Volume and Issue:
50(3), P. 212 - 225
Published: June 10, 2024
Menstrual
health
is
a
key
patient-reported
outcome
beyond
its
importance
as
general
indicator
of
and
fertility.
However,
menstrual
function
was
not
measured
in
the
clinical
trials
COVID-19
vaccines.
The
purpose
this
review
to
synthesise
existing
literature
on
relationship
between
vaccination
outcomes.
Molecular Pharmaceutics,
Journal Year:
2024,
Volume and Issue:
21(2), P. 393 - 409
Published: Jan. 8, 2024
Female
reproductive
health
has
traditionally
been
an
underrepresented
area
of
research
in
the
drug
delivery
sciences.
This
disparity
is
also
seen
emerging
field
mRNA
therapeutics,
a
class
medicines
that
promises
to
treat
and
prevent
disease
by
upregulating
protein
expression
body.
Here,
we
review
advances
therapies
through
lens
improving
female
health.
Specifically,
begin
our
discussing
fundamental
structure
biochemical
modifications
associated
with
mRNA-based
drugs.
Then,
discuss
various
packaging
technologies,
including
lipid
nanoparticles,
can
be
utilized
protect
transport
drugs
target
cells
Last,
conclude
usage
therapy
for
addressing
pregnancy-related
vaccination
against
sexually
transmitted
diseases
women.
Of
note,
highlight
relevant
clinical
trials
using
while
providing
their
corresponding
National
Clinical
Trial
identifiers.
In
undertaking
this
review,
aim
provide
background
understanding
its
specifically
address
issues
overarching
goal
information
toward
gender
certain
aspects
research.
Frontiers in Drug Safety and Regulation,
Journal Year:
2024,
Volume and Issue:
4
Published: Jan. 31, 2024
Introduction:
Menstrual
disorders
are
commonly
reported
after
COVID-19
vaccination
and
heavy
menstrual
bleeding
was
added
to
the
product
information
of
vaccines
Moderna
Pfizer.
The
aim
this
review,
using
a
systematic
search,
is
provide
an
overview
available
literature
on
risk
vaccination.
Methods:
review
conducted
according
Preferred
Reporting
Items
for
Systematic
reviews
Meta-Analysis
(PRISMA)
guidelines.
A
PubMed
search
performed
15
August
2023,
including
solely
quantitative
studies
in
English
Dutch.
Results:
total
61
were
included,
which
40
cross-sectional
studies,
18
cohort
three
self-controlled
case
series.
Outcomes
included
wide
variety
disorders,
changes
cycle
length
(
n
=
54),
amount
44),
menses
30),
experience
(pre)menstrual
pain
21),
breakthrough
18).
All
found
higher
percentage
at
least
one
disorder
first
different
types
doses.
Discussion:
In
conclusion,
evidence
suggests
that
may
cause
women
reproductive
age.
However,
there
need
more
longitudinal
because
important
limitations
study
designs
many
studies.
Although
short-lived
predominantly
mild,
it
healthcare
professionals
be
informed
about
these
potential
adverse
reactions
assess
events
clinical
trials
vaccines.
British Journal of Clinical Pharmacology,
Journal Year:
2023,
Volume and Issue:
89(10), P. 3126 - 3138
Published: May 24, 2023
During
the
COVID-19
vaccination
campaigns,
number
of
reports
menstrual
abnormalities
increased
rapidly.
Here,
we
describe
nature
and
potential
risk
factors
associated
with
based
on
spontaneously
reporting
data
as
well
from
a
prospective
cohort
event
monitoring
(CEM)
study
these
are
poorly
studied.Reports
received
by
Netherlands
Pharmacovigilance
Centre
Lareb
in
spontaneous
system
between
February
2021
April
2022
were
summarized.
In
addition,
logistic
regression
analysis
was
performed
reported
CEM
to
assess
association
person
characteristics,
prior
SARS-CoV-2
infection
use
hormonal
contraceptives
occurrence
after
vaccination.We
analysed
over
24
000
500
episodes
(among
16
929
included
women)
study.
The
showed
an
incidence
41.4
per
1000
women
aged
≤54
years.
Amenorrhoea/oligomenorrhoea
heavy
bleeding
collectively
accounted
for
about
half
all
reported.
Significant
associations
observed
age
group
25-34
years
(odds
ratio
2.18;
95%
confidence
interval
1.45-3.41)
Pfizer
vaccine
3.04;
2.36-3.93).
No
body
mass
index
presence
most
comorbidities
assessed.The
high
disorders
among
years,
this
observation
supported
reports.
This
suggests
that
relation
is
plausible
should
be
further
investigated.
Immunity Inflammation and Disease,
Journal Year:
2024,
Volume and Issue:
12(1)
Published: Jan. 1, 2024
The
current
study
aims
to
evaluate
the
impact
of
COVID-19
infection
and
vaccination
on
ovarian
reserve
by
detecting
anti-Mullerian
hormone
(AMH)
level.
Frontiers in Endocrinology,
Journal Year:
2024,
Volume and Issue:
15
Published: Oct. 4, 2024
The
COVID-19
pandemic
has
left
a
profound
mark
on
global
health,
leading
to
substantial
morbidity
and
mortality
worldwide.
Beyond
the
immediate
symptoms
of
infection,
emergence
“long
COVID”,
long-term
effects
SARS-CoV-2,
become
significant
public
health
concern.
Long
COVID
is
multifaceted
condition
affecting
various
organs
systems,
including
cardiovascular,
digestive,
nervous,
endocrine
systems.
Individuals
diagnosed
with
polycystic
ovary
syndrome
(PCOS)
may
face
an
increased
risk
severe
infection.
It
crucial
comprehend
how
long
affects
PCOS
patients
devise
effective
treatment
care
strategies.
Here,
we
review
detrimental
its
reproductive
function,
inflammation,
metabolism,
cardiovascular
body
composition,
lifestyle,
mental
in
PCOS.
We
offer
recommendations
for
post-covid-19
management
PCOS,
emphasizing
necessity
comprehensive,
multidisciplinary
approach
patient
care.
Furthermore,
discuss
prospective
research
directions,
highlighting
significance
continued
investigations
clinical
trials
evaluate
approaches
ramifications
individuals
Global Health & Medicine,
Journal Year:
2023,
Volume and Issue:
5(2), P. 112 - 117
Published: Feb. 10, 2023
On
December
7,
2022,
China's
National
Health
Commission
issued
the
Ten
New
Covid
Rules
lifting
dynamic
zero-COVID
policy.
In
interim,
vaccination
campaigns
continue
to
be
promoted.
We
assessed
potential
impacts
on
status,
perceptions,
and
attitudes
toward
COVID-19
vaccines
via
an
online
self-administered
questionnaire.
Among
1,170
participants,
1,142
(97.6%)
participants
were
vaccinated
against
COVID-19,
51.8%
(591/1,142)
have
already
received
booster.
More
than
half
of
who
ages
31
50
(51.8%).
Participants
believed
following
strategies
could
improve
rate:
timely
feedback
data
(such
as
safety,
efficacy,
other
issues
public
concern)
from
authoritative
media
(95.6%),
increasing
number
sites
availability
using
more
convenient
methods
making
appointment
(95.2%),
recommendations
friends
relatives
(94.8%),
presenting
qualifications
staff
performing
(89.1%).
measures,
including
targeted
measures
for
different
age
groups
safety
efficacy
media,
are
likely
help
rates.
Middle East Fertility Society Journal,
Journal Year:
2025,
Volume and Issue:
30(1)
Published: Feb. 28, 2025
Abstract
Introduction
and
objectives
Women’s
reproductive
fertility
health
may
be
influenced
by
COVID-19.
However,
data
on
whether
SARS-CoV-2
infection
affects
menstrual
pattern,
volume,
sex
hormone
levels
remain
limited.
This
study
aimed
to
investigate
changes
in
the
pattern
volume
of
menstruation
as
well
FSH,
LH,
TSH,
prolactin,
AMH
women
age
following
Patients
methods
In
this
cross-sectional
study,
we
enrolled
30
healthy
(aged
18–36
years)
who
presented
with
male-factor
infertility.
Participants
were
included
if
they
non-menopausal,
had
negative
pregnancy
test
results,
no
history
significant
medical
illness
or
drug
treatment.
Women
using
contraceptive
treatments
undergone
specific
therapeutic
procedures
medications
for
infertility
excluded.
Additionally,
vaccinated
against
COVID-19
All
participants
a
confirmed
diagnosis
(positive
PCR
test).
To
minimize
acute-phase
fluctuations,
re-evaluated
5-
7-month
post-infection.
We
compared
pre-
post-infection
from
their
records,
used
screening
checklist
assess
(e.g.,
oligomenorrhea,
polymenorrhea)
volume.
Each
participant
effectively
served
her
own
control.
Data
analyzed
at
95%
confidence
level
P
<
0.05
considered
significant.
Results
The
mean
(±
SD)
was
29.23
±
3.45
years.
Nearly
one-third
(33%)
reported
new-onset
after
COVID-19,
including
oligomenorrhea
(20%)
polymenorrhea
(13%).
No
experienced
amenorrhea.
Post-infection
showed
slight
increase
prolactin
decrease
AMH;
however,
only
TSH
exhibited
statistically
rise.
Changes
not
associated
treatment
methods,
hospitalization,
pulmonary
involvement.
By
contrast,
those
hospitalization
more
frequent
alterations
(
=
0.041
0.006,
respectively).
Pulmonary
involvement
did
significantly
impact
pattern.
Conclusion
linked
increases
notable
shifts
among
age,
while
other
hormones
remained
largely
unchanged.
Further
research
larger
sample
sizes
formal
control
group
is
needed
clarify
these
observations.
Obstetrics and Gynecology International,
Journal Year:
2025,
Volume and Issue:
2025(1)
Published: Jan. 1, 2025
Purpose:
This
study
aimed
to
evaluate
the
effect
of
COVID-19
infection
and
vaccination
on
all
menstrual
cycle
parameters
in
women
reproductive
age
group,
18-45
years,
at
a
tertiary
care
hospital.
Methods:
A
single-center,
descriptive
cross-sectional
was
done
from
January
2,
2023,
June
24,
2023.
Sampling
nonprobabilistic
purposeful.
Participants
were
recruited
via
calls,
in-person
interviews,
online
surveys.
total
931
participants
recruited,
which
141
eligible
for
study.
Descriptive
statistics
performed
variables.
Pearson's
chi-square
test
compare
categorical
variables
among
different
groups,
Wilcoxon
matched
pair
signed-rank
patterns
before
after
vaccination.
Simple
linear
regression
multiple
analysis
wherever
necessary.
p
<
0.05
considered
statistically
significant.
Results:
The
median
29
years.
Those
who
reported
abnormalities
mainly
group
18-27
(n
=
62,
44.0%),
resided
an
urban
locality
123,
87.2%),
employed
(full-time/part-time)
57,
40.4%).
Of
42
with
changes,
27
(64.3%)
experienced
changes
post-COVID-19
their
first
dose
15
(35.7%)
dose.
In
this
continue
experience
cycles.
Analysis
showed
that
having
severe
symptoms
more
likely
have
earlier
onset
(beta
-2.072,
p=0.040).
above-normal
BMI
increased
pain/cramps
during
menses
0.236,
p=0.0.013).
students/employed
-0.365,
p=0.001)
0.182,
p=0.024)
mood
swings/tension/irritability.
On
comparing
duration
postvaccination
it
found
latter
had
late-onset
short-term
effect,
while
former
early-onset
long-term
menses.
Conclusion:
Our
shows
there
is
evidence
irregularities
following
revealed
influence
cycles,
posing
higher
risk,
but
effects
menstruation
independent
one
another
are
be
studied
further.
Therapeutic Advances in Medical Oncology,
Journal Year:
2025,
Volume and Issue:
17
Published: May 1, 2025
Background:
The
initial
response
to
coronavirus
disease
2019
(COVID-19)
in
Ontario
included
suspension
of
cancer
screening
programs
and
deferral
diagnostic
procedures
many
treatments.
Although
the
short-term
impact
these
measures
on
female
cancers
is
well
documented,
few
studies
have
assessed
mid-
long-term
impacts.
Objectives:
To
compare
annual
billing
prevalence
incidence
rates
during
COVID-19
period
(2020–2022)
pre-COVID-19
levels
(2015–2019).
Design:
Retrospective
analysis
aggregated
claims
data
for
codes
from
Health
Insurance
Plan
(OHIP).
Methods:
Linear
regression
was
used
fit
(2015–2019)
each
OHIP
code
extrapolate
counterfactual
values
years
2020–2022.
Excess
were
calculated
as
difference
between
projected
actual
year.
Results:
In
2020,
cervical,
breast,
uterine,
ovarian
decreased
relative
that
year
by
−50.7/100k,
−13.9/100k,
−3.5/100k,
−3.8/100k,
respectively.
reverse
observed
2021
with
rate
increases
47.8/100k,
59.1/100k,
2.5/100k,
3.7/100k,
2022,
excesses
further
amplified,
especially
cervical
breast
(111.2/100k
78.67/100k,
respectively).
net
excess
patient
2020–2022
largely
positive
all
types
(108.3/100k,
123.7/100k,
5.2/100k,
1.8/100k,
Analysis
showed
similar
trends.
Conclusion:
expected
decreases
2020
followed
large
resulting
a
cumulative
period.
Further
research
required
assess
nature
changes.
